Nektar Therapeutics has concluded target enrolment in the Phase IIb REZOLVE-AA trial of its investigational biologic therapy, ...

Therapeutics announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lemaitre Vascular (LMAT – Research Report), ...

William Blair reiterated their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report ...

Native Instruments' NKS Hardware Partner Program launches today, bringing NKS compatibility to owners of a handful of its ...

Nektar announces clinical trial agreement to evaluate rezpegaldesleukin in patients with new onset type 1 diabetes mellitus: San Francisco Tuesday, February 25, 2025, 18:00 Hrs [I ...

Nektar Therapeutics’s NKTR share price has surged by 22.00%, which has investors questioning if this is right time to sell.

Nektar Therapeutics is waiting on multiple data readouts for its lead drug bempegaldesleukin paired with strategic partner Bristol-Myers Squibb’s checkpoint inhibitor Opdivo, but that hasn’t ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced today that its drug candidate, rezpegaldesleukin, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ...

Shares of Nektar Therapeutics (NKTR) have been struggling lately and have lost 11.5% over the past four weeks. However, a hammer chart pattern was formed in its last trading session, which could ...

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are the ...